Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?

  • Sai-Hong Ou, Ross Soo
  • Drug Design Development and Therapy, October 2015, Taylor & Francis
  • DOI: 10.2147/dddt.s52787

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.2147/dddt.s52787